Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHAT | P28329 | 1/20 | 0.66 |
| ▸ | RELA | Q04206 | 2/20 | 0.63 |
| ▸ | MAOB | P27338 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.56 |
| ▸ | FBP1 | P09467 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446280 | 1.00 | CHAT (0.66) | CHATRELAMAOBCYP1A2CYP2C9 | |
| SCHEMBL699874 | 1.00 | CHAT (0.66) | CHATRELAMAOBCYP1A2CYP2C9 | |
| SCHEMBL699364 | 0.93 | CHAT (0.67) | CHATRELAMAOBCYP1A2CYP2C9 | |
| SCHEMBL699365 | 0.93 | CHAT (0.67) | CHATRELAMAOBCYP1A2CYP2C9 | |
| SCHEMBL13291663 | 0.91 | MAOB (0.61) | CHATRELAMAOBCYP1A2CYP2C9 | |
| SCHEMBL28626001 | 0.88 | RELA (0.67) | CHATRELAMAOBCYP1A2CYP2C9 | |
| SCHEMBL700046 | 0.88 | RELA (0.67) | CHATRELAMAOBCYP1A2CYP2C9 | |
| SCHEMBL700045 | 0.88 | RELA (0.67) | CHATRELAMAOBCYP1A2CYP2C9 | |
| SCHEMBL30081496 | 0.88 | RELA (0.67) | CHATRELAMAOBCYP1A2CYP2C9 | |
| (Z)-1,2-Diphenylethene SCHEMBL28535457 | 0.85 | TSHR (0.65) | CHATMAOBMAOANFE2L2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021074275-A1 | EFFECTIVE PHOTOMODULATION OF LANTHANIDE (III) ION LUMINESCENCE IN THE VISIBLE OR NEAR-INFRARED RANGE | UNIVERSITE DE RENNES 1 (FR) | 2021-04-22 | — | — | WO | disclosed |
| CN-110256192-A | It is a kind of using alcohol be hydrogen source Photocatalysis selectivity synthesis cis and trans olefins process | 南通大学 | 2019-09-20 | — | — | CN | disclosed |
| CN-110218141-A | A kind of Photocatalysis selectivity synthesis Z- and E- olefins process | 南通大学 | 2019-09-10 | — | — | CN | disclosed |
| CN-109134172-A | The alcohol hydrogen supply iridium catalytic selectivity of ligand regulation synthesizes Z- and E- olefins process | 南通大学 | 2019-01-04 | — | — | CN | disclosed |
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| US-9868873-B2 | Photochromic security enabled ink for digital offset printing applications | XEROX CORPORATION (US) | 2018-01-16 | — | — | US | disclosed |
| US-9718763-B2 | Catalytic ester decarbonylation | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM | 2016-10-06 | — | — | US | disclosed |
| US-20160194276-A1 | CATALYTIC ESTER DECARBONYLATION | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2016-07-07 | — | — | US | disclosed |
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | disclosed |
| US-20050244744-A1 | Method for forming temporary image | XEROX CORPORATION | 2005-11-03 | — | — | US | disclosed |
| US-20050244743-A1 | Reimageable medium | XEROX CORPORATION. | 2005-11-03 | — | — | US | disclosed |
| EP-1591830-A2 | Reimageable medium | Xerox Corporation (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1591831-A2 | Reimageable medium with light absorbing material | Xerox Corporation (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1591829-A1 | Method for forming temporary image | Xerox Corporation (US) | 2005-11-02 | — | — | EP | disclosed |
| US-5759729-A | A DRY TONER COMPRISING A RESIN, PHOTOCHROMATIC SPIROPYRAN, -OXAZINE OR -THIOPYRAN DYE AND A CHARGE CONTROL AGENT;ELECTROGRAPHY; XEROGRAPHY | XEROX CORPORATION (US) | 1998-06-02 | — | — | US | disclosed |
| US-5710420-A | Method for embedding and recovering machine-readable information | XEROX CORPORATION (US) | 1998-01-20 | — | — | US | disclosed |
| US-5633109-A | Ink compositions with liposomes containing photochromic compounds | XEROX CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| US-5593486-A | Photochromic hot melt ink compositions | XEROX CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| US-5551973-A | LIQUID CRYSTAL GEL PHASE, MICROEMULSION PHASE | XEROX CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | CUTA, TSLP, ELANE | CHAT 2682/4885RELA 29/4885MAOB 961/4885 |
| US-20160194276-A1 | CATALYTIC ESTER DECARBONYLATION | DECR1, C1S, CBR3 | CHAT 599/4885RELA 1378/4885MAOB 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.